Blitz Bureau
NEW DELHI: Two things happened in Indian public health this month that will matter far more in a monsoon five years from now than they do this week. The Central Drugs Standard Control Organisation has granted marketing authorisation to Qdenga, a live attenuated tetravalent dengue vaccine developed by Takeda GmbH of Germany, for the prevention of dengue in people aged 4 to 60. The vaccine is given as two 0.5 ml subcutaneous doses three months apart.
Dengue is a peculiarly difficult disease to vaccinate against, which is why an authorisation of this kind is significant beyond the product itself. The virus circulates as four distinct serotypes, and immunity to one can, in certain circumstances, worsen a subsequent infection with another — which is why a tetravalent vaccine covering all four is the design that matters, and why regulators everywhere have examined this class of product with unusual care. For India, where dengue arrives with the monsoon across a very large part of the country and where the burden falls heavily on urban and peri-urban populations, the arrival of a licensed option changes what a public health department is able to plan for.
Four serotypes, one vaccine: dengue’s biology is what has made it hard to vaccinate against, and why a licensed tetravalent option changes what a district health plan can contain.
A vaccine licence is a starting line, not a finish. What decides the outcome is the laboratory that spots the outbreak and the clinic that can reach the street it started on.
At a Glance
• Authorisation: Qdenga, granted marketing authorisation by the CDSCO
• Indication: prevention of dengue in people aged 4 to 60
• Type: live attenuated tetravalent vaccine, covering all four dengue serotypes
• Schedule: two 0.5 ml subcutaneous doses, three months apart
• Developer: Takeda GmbH, Germany
• Laboratories: under PM-ABHIM, ICMR is upgrading Viral Research and Diagnostic Laboratories into Infectious Disease Research and Diagnostic Laboratories
• Technology transfer: ICMR has facilitated the licensing of three indigenous biomedical technologies to Indian pharmaceutical and vaccine manufacturers
• Digital health: an IndiaAI–ICMR agreement covers AI in diagnostics, disease prediction and public health management
• Coverage: Ayushman Bharat was extended to West Bengal from July 2026, absorbing existing Swasthya Sathi beneficiaries
The second development is less visible and arguably more consequential. Under the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission, the Indian Council of Medical Research is upgrading the country’s Viral Research and Diagnostic Laboratories into Infectious Disease Research and Diagnostic Laboratories — a change of mandate as much as of equipment. A viral research laboratory answers the question “is this the virus we suspect?” An infectious disease laboratory is built to answer the broader and harder question of what is actually circulating in a district, including bacterial and fungal pathogens and drug resistance patterns. That is the difference between confirming an outbreak and detecting one. Alongside it, ICMR has licensed three indigenous biomedical technologies to Indian pharmaceutical and vaccine manufacturers, and has signed an agreement with IndiaAI covering artificial intelligence in diagnostics, disease prediction and public health management.
Read together, these are the components of a system rather than a set of separate announcements, and the constructive agenda is about connecting them. A vaccine reduces disease only where it is delivered, which means the practical questions now are price, cold-chain reach into smaller towns, and clear clinical guidance to physicians on who should receive it and when. Surveillance data is only useful at the speed it travels, which makes the laboratory network’s value dependent on how quickly a district result reaches a state and national picture. And artificial intelligence applied to health data is powerful in proportion to the quality of the data underneath it, which puts a premium on consistent, well-governed reporting from ordinary district facilities rather than only from research centres. India has, over the past decade, built the pieces — insurance coverage now extending across almost every state, a domestic vaccine manufacturing base of global scale, and a laboratory network with national reach. The gain available now comes from making them talk to each other.
